Kuria Therapeutics, a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic disease, will be holding meetings with investors and other parties during the 44th Annual J.P. Morgan Healthcare Conference, January 11-15 2026, in San Francisco, California. Kuria's Chief Executive Officer, Dr. Keith Ward, will be holding one-on-one meetings during the conference to discuss the latest company and data updates for Kuria's lead program transforming treatm